COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

Introduction

Breast cancer is the most prevalent malignancy in patients with coronavirus disease 2019 (COVID-19). However, vaccination data of this population are limited.

A cross-sectional study of COVID-19 vaccination was conducted in China. Multivariate logistic regression models were used to assess factors associated with COVID-19 vaccination status.

Of 2,904 participants, 50.2% were vaccinated with acceptable side effects. Most of the participants received inactivated virus vaccines. The most common reason for vaccination was “fear of infection” (56.2%) and “workplace/government requirement” (33.1%). While the most common reason for nonvaccination was “worry that vaccines cause breast cancer progression or interfere with treatment” (72.9%) and “have concerns about side effects or safety” (39.6%). Patients who were employed (odds ratio, OR = 1.783, p  = 0.015), had stage I disease at diagnosis (OR = 2.008, p  = 0.019), thought vaccines could provide protection (OR = 1.774, p  = 0.007), thought COVID-19 vaccines were safe, very safe, not safe, and very unsafe (OR = 2.074, p  < 0.001; OR = 4.251, p  < 0.001; OR = 2.075, p  = 0.011; OR = 5.609, p  = 0.003, respectively) were more likely to receive vaccination. Patients who were 1–3 years, 3–5 years, and more than 5 years after surgery (OR = 0.277, p  < 0.001; OR = 0.277, p  < 0.001, OR = 0.282, p  < 0.001, respectively), had a history of food or drug allergies (OR = 0.579, p  = 0.001), had recently undergone endocrine therapy (OR = 0.531, p  < 0.001) were less likely to receive vaccination.

COVID-19 vaccination gap exists in breast cancer survivors, which could be filled by raising awareness and increasing confidence in vaccine safety during cancer treatment, particularly for the unemployed individuals.